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p97 protein is a highly conserved, abundant, functionally diverse, structurally dynamic 
homohexameric AAA enzyme-containing N, D1, and D2 domains. A truncated p97 protein 
containing the N and D1 domains and the D1-D2 linker (ND1L) exhibits 79% of wild-type (WT) 
ATPase activity whereas the ND1 domain alone without the linker only has 2% of WT activity. 
To investigate the relationship between the D1-D2 linker and the D1 domain, we produced p97 
ND1L mutants and demonstrated that this 22-residue linker region is essential for D1 ATPase 
activity. The conserved amino acid leucine 464 (L464) is critical for regulating D1 and D2 ATPase 
activity by p97 cofactors p37, p47, and Npl4-Ufd1 (NU). Changing leucine to alanine, proline, or 
glutamate increased the maximum rate of ATP turnover (kcat) of p47-regulated ATPase activities 
for these mutants, but not for WT. p37 and p47 increased the kcat of the proline substituted 
linker, suggesting that they induced linker conformations facilitating ATP hydrolysis. NU 
inhibited D1 ATPase activities of WT and mutant ND1L proteins, but activated D2 ATPase 
activity of full-length p97. To further understand the mutant mechanism, we used single-
particle cryo-EM to visualize the full-length p97L464P and revealed the conformational change of 
the D1-D2 linker, resulting in a movement of the helix-turn-helix motif (543-569). Taken 
together with the biochemical and structural results we conclude that the linker helps maintain 
D1 in a competent conformation and relays the communication to/from the N-domain to the D1 
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 p97, also known as VCP (valosin-containing protein), TER (translational endoplasmic 
reticulum ATPase, in mammals), VAT (valosin-containing protein-like ATPase of Thermoplasma 
acidophilum, in archaea) and Cdc48p (in yeast), is a ubiquitous type II ATPase protein. It is 
highly conserved and plays essential roles in multiple cellular processes, including protein 
quality and cell cycle control [1-5], ubiquitin-proteasome system (UPS) [6, 7], transcriptional 
activation [8], DNA-damage repair [9] and autophagy [10-13]. The involvement of p97 in all 
major proteolysis pathways makes it a central player in cellular homeostasis. Given its 
prominent role in eukaryotic cells, p97 malfunction is associated with human disease [14-17]. 
Single amino acid mutations in p97 (e.g., R155H, Fig. 1A) cause multisystem proteinopathy 
type 1 (MSP1), also known as inclusion body myopathy with early-onset Paget disease of the 
bone and frontotemporal dementia (IBMPFD). Some p97 mutations caused amyotrophic lateral 
sclerosis (ALS) [18]. Variants in p97 have been identified in 2% of familial IBMPFD cases [19-
21].  
p97 is a 540-kDa homo-hexamer (6✕89 kDa) in which each monomer contains an N-
terminal domain (NTD, residues 1-184) and two tandem AAA+ ATPase domains, D1 (residues 
211-459) and D2 (residues 482-762) domains, and a C-terminal tail (residues 763 to 806) (Fig. 
1A). The D1 and D2 domains contain highly conserved Walker A and B motifs and a second 
region of homology (SRH). During an ATPase cycle, the D2 domain undergoes significant 
conformational changes, whereas ATP hydrolysis induces only minor changes in D1. The D1 
domain is required to form stable hexamers, regardless of the nucleotide-binding state [22, 
23]. Cooperativity between the D1 and D2 domains is essential for competent ATPase function 
[24]. However, the mechanisms of motion transmission and crosstalk between the two 
domains remain to be elucidated. 
Both D1 and D2 domains are organized into a double-ring structure. Cryo-EM 
structures of full-length p97 showed that the NTD adopts positions up-conformation, down-
conformation, and mobile [25, 26]. The NTD binds to various p97 cofactors, which coordinate 
p97 involvement in major cellular pathways. The largest group of known p97 cofactors are 
proteins that contain a ubiquitin-regulatory X (UBX) domain (13 members) [27]. The group is 
further subdivided based on the presence of an N-terminal ubiquitin-associated (UBA) 
domain, versus UBX-only proteins. Examples are p37 (UBX-only) and p47 (UBA-UBX) [27, 
28]. The UBA domain binds the ubiquitinated substrates, and the UBX domain mediates 
interactions with p97. p47 was the first discovered p97 UBX cofactor and is required for p97-
mediated membrane fusion [29, 30]. p37 is highly homologous to p47 in protein sequences but 
is involved in distinct pathways required for Golgi and endoplasmic reticulum (ER) biogenesis 
[31]. One of well- characterized p97 cofactors is a heterodimer of Npl4 and Ufd1 (NU). It 
binds to p97 at distinct sites to form a complex with the stoichiometry of one NU heterodimer 
per p97 hexamer and is involved in p97-dependent processes [32-35]. Npl4 is an effective 
target of the potential anti-cancer drug, disulfiram [36, 37]. 
The N-D1 linker (residues 185-210) and the D1-D2 linker (residues 460-481) connect 
NTD-D1 and D1-D2 domains, respectively (Fig. 1A). This structural arrangement is also found 
in another AAA ATPase, N-ethylmaleimide-sensitive factor (NSF), the closest homolog of p97. 
In NSF, the N-D1 linker is involved in motion transmission from the D1 domain to the N-
domain, as well as auto-inhibition of NSF activity [38]. Previous work on p97 suggests that 
flexibility in the D1-D2 linker region is required for ATP hydrolysis-dependent motion 
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endoplasmic reticulum-associated degradation (ERAD) substrate, T cell receptor alpha chain 
fused to GFP (TCR-α-GFP) [39, 40]. p97 proteins containing only the NTD and D1 domains 
without the D1-D2 linker domain (ND1) exhibit only 1.4% of the ATPase activity of the full-
length wild-type p97 (p97WT) protein. In contrast, NTD and D1 domains containing the D1-D2 
linker (ND1L) exhibit 79% of p97WT activity [24]. Thus, the linker region is crucial for D1 
ATPase competence, but it is unclear how the D1-D2 linker contributes to D1 ATPase activity. 
The D1-D2 linker region of p97 is important for motion transmission and D1 activity 
[39-41]. Tang and Xia reported that the linker activates D1 by breaking the six-fold symmetry 
of the D1 ring and that half of the D1-D2 linker region is highly conserved from humans to 
fungi [42]. Our work showed that disease-causing mutations in p97 are associated with 
improper cofactor-dependent regulation of ATPase activity, demonstrating the importance of 
cofactor regulation to p97 function [43]. In addition, MSP1 disease mutations caused 
differential binding of adaptor proteins (p37 and p47) to the NTD of p97 in cells [44, 45]. 
The present study connects these areas of p97 mechanics by evaluating D1-D2 linker 
region participation in cofactor-regulated ATPase activity and in regulating the N-domain 
conformation via solving full-length p97L464P structures using single-particle cryo-EM. We studied 
the effect of three p97 cofactors on D1-D2 linker mutants constructed from full-length p97 and 
on a truncated p97 protein containing the N and D1 domains and the D1-D2 linker (ND1L). 
Our results suggest that the D1-D2 linker region of WT p97 has essential roles in cofactor-
regulated ATPase function and its conformation changes will relay to the N-domains, D1 and 
D2 ATP binding sites. This provides further insight into why p97 mutants cause the 
accumulation of the ERAD substrate TCR-ɑ-GFP [39], and highlights the importance of linker 
region in cofactors-regulated p97 ATPase function. 
Results 
L464 mutations affect the degradation of ubiquitin-proteasome substrate UbG76V-GFP 
The N-D1 linker and the D1-D2 linker (residues 460-481) connect NTD-D1 and D1-D2 
domains (Fig. 1A). The p97 crystal structure features an NTD linked to two stacked AAA 
domains (Fig. 1B). The NTD binding site for p47-UBX (pink; Fig. 1C) resides 37.4 Å and 51.6 
Å away from the D1 and D2 nucleotide binding sites, respectively. Therefore, cofactor 
regulation of ATPase kinetics must involve interactions relayed through the NTD, D1, and D2 
domains, as well as the linker regions. We are intrigued by the interesting model and the result 
suggested that the D1-D2 linker region of p97 is important for motion transmission and to 
activate D1 activity [39-41]. Li and coworkers demonstrated that p97 mutants L464A, L464E 
and L464P cause substantial accumulation of TCR-α-GFP, indicating a dramatic loss of ERAD 
activity [39]. To determine whether the L464 amino acid is critical for the degradation of 
another p97 dependent proteasome substrate, we expressed L464A, L464E or L464P p97 
plasmids in HeLa cells that stably expressed UbG76V-GFP [46]. We observed an accumulation 
of UbG76V-GFP in the L464A, L464E and L464P mutants. We used a p97 ATPase dead mutant 
as a positive control, which was created by mutating the conserved glutamate residues of the 
Walker B motifs to glutamines in both the D1 and D2 domains and resulting in single mutants 
D1-E305Q and D2-E578Q. The mutants were then combined as a double mutant D1-
E305Q/D2-E578Q (QQ). This led to the double mutant that allows to bind ATP but is defective 
in hydrolysis [47].  Strong accumulation of UbG76V-GFP was also observed in QQ, the ATPase 
dead mutant. (Fig. S1). We confirmed that the conserved L464 is a critical amino acid for p97 
to maintain its role in mediating degradation of p97-dependent ubiquitin-proteasome 
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464 is crucial for proper p97 function, we then evaluated the biochemical and structural effect 
of L464 by study the effect on cofactor regulated ATPase activity of these mutants. We 
selected three previously studied cofactors, p47, p37 and Npl4-Ufd1 [43, 49].  
D1-D2 linker mutants are defective in p47 regulated p97 ATPase activity 
We and others have previously used cofactor regulated ATPase activity as a function 
readout of cofactor binding to N-domain and communicate to D1 and D2 activity activities [43, 
49]. To evaluate whether the conserved L464 is critical for the cofactor-regulated p97 ATPase 
activity, we purified full-length L464A, L464E and L464P p97 mutants. Consistent with previous 
reports [39], we found that the basal ATPase activity of mutants L464A and L464E was similar 
to that of p97WT (Fig. 2A). However, the proline mutant L464P had a two-fold reduction in basal 
ATPase activity (49% of p97WT), suggesting that the proline side chain possibly changes the 
D1-D2 linker conformation thereby reducing the basal ATP hydrolysis of p97 [40]. We then 
performed cofactor titration experiments on these three L464 mutants to determine the effects 
of these mutations on cofactor-regulated ATPase activity. Regulation of p97WT activity by p47 is 
biphasic, with strong inhibition at lower concentrations of p47 (Phase 1), and less inhibition at 
higher stoichiometries of the cofactor (Phase 2, or the “rebound” phase) [43]. With the three 
L464 mutants, however, Phase 1 inhibition at low concentrations of p47 was abolished (Fig. 
2B), suggesting that this conserved residue is required for proper cofactor-regulation of the D1 
and D2 domains. Moreover, during Phase 2, a >2.2-fold increase in ATPase activity was 
observed for p97L464A and p97L464E and 3.8-fold increase was for p97L464P -- far beyond the 
usual p97WT level (0.8-fold). It appears that the conserved L464 residue within the D1-D2 linker 
plays an important role in p47-regulated p97 ATPase activity. This p47 concentration-
dependent effect is similar to that of the D1-E305Q mutant, in which the D1 ATPase is unable 
to perform ATP hydrolysis (Fig. S2A). Thus, the linker mutants seem to block communication 
between D1 and D2, and the L464 linker residue is critical for mediating D2 domain cross 
inhibition by D1 during p47 binding. 
L464 mutants display p37 and NU activation profiles similar to those for p97WT 
Instead of biphasic regulation of p47, we have shown that p37, a p47 homolog, 
activates the p97WT function (4.2-fold) [31, 43]. In the presence of p37, the D1-D2 linker 
mutants followed an activation profile similar to profiles for p97WT. L464A and L464E had 
slightly decreased activation by p37 (3.1- and 3.3-fold increases in ATPase activity, 
respectively), whereas the increase in ATPase activity for L464P reached a maximum of 5.8-
fold at 800 nM p37 (Fig. 2C). We further investigated the binding of the Npl4-Ufd1 (NU) with 
p97 ATPase. Electron microscopic (EM) study demonstrated that the NU interacts with p97-
NTD via the Npl4-UBX-L domain, which induces a conformational change for ATP hydrolysis 
[32, 34, 35, 50]. Our titration results identified the NU as an activator of p97WT ATP hydrolysis, 
starting at 20 nM and reaching a maximal 2.2-fold increase in activity at 200 nM, consistent 
with previously published studies (Fig. 2D) [49, 51]. Using the Walker B mutants of p97 (D1-
E305Q and D2-E578Q) (Fig. S2B), we showed that D1-E305Q and p97WT have similar titration 
results. The result suggests that the NU activates D2 ATPase, because the D1 dead mutant 
(E305Q-p97) can hydrolyze ATP by the D2 ATPase, but not the D1 ATPase. The NU-mediated 
increases in ATPase activity (Fig. 2D) for linker mutants L464A and L464E were slightly less 
than the increases for p97WT. The activation of the p97L464P mutant was 4.4-fold, about twice 
that of the p97WT, and similar to the effect of p37. This supports that cofactor regulation by p37 
and NU is affected by D1-D2 linker mutations to some extent. 
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To characterize the changes observed during the cofactor titrations, we measured the 
apparent steady-state kinetic constants for ATP hydrolysis for each enzyme-cofactor complex. 
The p97L464P mutant cofactor interactions produced the most significant changes in Michaelis-
Menten (MM) curves (Fig. 3A). The apparent kinetic constants are summarized in Tables S1 
and their ratio to without cofactor are shown in Table S3. The apparent maximum rate of ATP 
turnover (kcat) for the p97
L464P mutant was 3.3-fold lower than for p97WT (1.5 versus 4.7 min-1) 
(Fig. 3B). However, the apparent Michaelis constant (Km) for p97
L464P did not differ substantially 
from the p97WT (Fig. 3C). Thus, the apparent overall catalytic efficiency (kcat/Km) of the p97
L464P 
mutant was 3.8-fold lower than that of p97WT, primarily due to the decreased rate of ATP 
hydrolysis (Fig. 3D). p97L464A and p97L464E mutants had apparent kcat, apparent Km, and apparent 
kcat/Km values within 2-fold of p97
WT values (Fig. 3B-D). 
p47 decreased the apparent ATP turnover number slightly for p97WT but increased the 
apparent kcat for all three L464 mutants (Fig. 3B), most pronounced for p97
L464P (3.3-fold; Fig. 
3B) and comparable to levels for p97WT alone (5.0 min-1 vs. 4.7 min-1, respectively). The 
apparent Km values of p97
WT and all three mutants, L464A, L464E and L464P, were all 
decreased by p47 compared to its basal ATPase activity without p47, supporting an 
interpretation that L464 mutations primarily affect p47-mediated changes in hydrolysis 
(apparent kcat, in Fig. 3B) more than that of ATP binding (apparent Km, in Fig. 3C). Compared to 
WT p97, the apparent Km value is generally higher for the Linker mutants, thus the linker does 
affect ATP binding in the absent of p47. The presence of p47 rescued the defect of L464P in 
ATP hydrolysis (apparent kcat) and made WT p97 and L464P similar. We previously 
demonstrated that p47 inhibits D2 ATPase hydrolysis, which requires active D1 hydrolysis 
[43]. Here, our results suggest that during p47 binding, L464 is required for the cross-inhibition 
of D1 on D2-driven ATP hydrolysis. Unlike p47, p37 and NU complexes produced similar 
steady-state kinetic profiles within 2-fold of p97WT values across the three mutants. This 
suggests that the distinct conformational changes that occur during p37 and NU binding were 
not significantly impaired by these L464 mutations. Thus, p97 control by p37 and NU differs 
from p47-mediated regulation. 
Taken together, these findings indicate that the L464, located between the D1 and D2 
domains (Fig. 1C), does not affect the apparent Michaelis constant (Km) (Fig. 3C) but is instead 
critical for the hydrolysis steps of both basal and cofactor-regulated ATPase cycles of full-
length p97. The p97L464P mutant had a 3.1-fold reduction in the kcat for basal ATPase activity, 
which was rescued by all three cofactors, shown by increases in apparent kcat of 3.3-fold (with 
p47), 6.0-fold (with p37), and 4.2-fold (with NU). 
Elucidating the effect of linker mutants on D1 ATPase activity 
Recently, NMR (nuclear magnetic resonance) spectroscopic analysis revealed that the 
WT-ND1L (residues 1-480 of p97) binding to monomeric p47 in solution with a Kd values of 
230 nM determined by ITC [52]. The ND1L p97 protein is a robust, catalytically competent 
ATPase, similar to the D1 ATPase in full-length p97 [24]. Notably, ND1 proteins lacking the D1-
D2 linker are enzymatically dead, indicating that the linker region is vital to D1 activity [24]. 
Therefore, ND1L can be used to scrutinize the D1-specific changes in ATPase kinetics for the 
linker mutants, with and without cofactor binding. Like the full-length version, L464E-ND1L 
exhibited basal ATPase activity (81.6%) comparable to activity for WT-ND1L. In contrast, 
L464P-ND1L retained only 1.7% of the activity of WT-ND1L (Fig. 4A), a level similar to that of 
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ND1L significantly impairs the alignment of residues into the proper conformation so diminish 
the ability of D1 to hydrolyzing ATP as if the linker is completely removed. (Fig. 4A). 
Size-exclusion chromatographic (SEC) profiles confirmed that the loss of activity in 
L464P-ND1L was not due to differences in the formation of proper oligomers, as compared to 
WT-ND1L. All three proteins had the same elution volume, and the oligomeric state of each 
was calculated to be 7.6 (Table S4). Based on published ND1 structures, we think ND1L is a 
hexamer; the calculated 7.6 oligomeric state for all of the ND1L proteins suggested their 
oligomeric state is the same.  One crystal structure of p97 D2 domain showed a heptamer but 
the rest of p97 structures are all hexamers [53]. As with the full-length protein, dose-dependent 
cofactor titrations found differences in cofactor-regulated ATPase activity in wild-type ND1L 
versus ND1L mutants. In the presence of p47, the titration curves of WT-ND1L and L464E-
ND1L remained flat, with activities close to baseline levels (Fig. 4B). However, L464P-ND1L 
had a dramatic 12-fold increase in ATPase activity at 800 nM p47, suggesting that the p47 
binding to NTD causes a conformational change that alleviates the L464P defects in D1 
hydrolysis. 
We observed minor increases in the ATPase activity (1.3-fold) of the WT-ND1L with p37 
(Fig. 4C), and a 3.7-fold increase for full-length p97WT (Fig. 2C), suggesting that p37 activation 
occurs primarily at D2 ATPase, consistent with previous data [43]. L464P-ND1L ATPase 
activity rose 4.7-fold with 800 nM p37. Heterodimer NU is an activator of full-length p97 (Fig. 
2D). Yet, we found that NU inhibited hydrolysis in three ND1L proteins (Fig. 4D). For L464P-
ND1L, we were unable to detect activity above background levels when using 25 nM 
monomer, due to the low basal activity of L464P-ND1L and the inhibitory effect of NU. We 
therefore increased the L464P-ND1L monomer concentration to 125 nM (5-fold) for NU 
titration. Still, we did not detect activity changes over 0.4 to 600 nM NU. At 800 nM (the 
equivalent of 160 nM NU per 25 nM L464P-ND1L monomer), we observed nearly 2-fold 
inhibition. WT-ND1L and L464E-ND1L variants followed similar titration curves, with inhibition 
starting at 60 nM, and about 2-fold decreases in ATPase activity at 200-800 nM NU (Fig. 4D).  
To examine NU-mediated D1 and D2 ATPase activities in full-length p97, we used 
Walker B mutants, D1- E305Q and D2-E578Q, which allow ATP and ADP binding but block 
activation of hydrolysis. The NU titration curve for p97WT was similar to the curve for D1-305Q 
p97, whereas the D2-E578Q curve was relatively flat, with a small decrease (Fig. S2B). NU 
appears to inhibit D1 activity slightly while activating D2 activity in p97WT. Comparison of 
titrations for ND1L (Fig. 4D) and D2-E578Q (Fig. S2B) suggest that NU inhibits D1 activity 
more when the D2 domain is absent.  
Steady-state kinetic analysis of ND1L-domain mutants 
The apparent steady-state kinetic constants of the ND1L proteins (Tables S2 and S3) 
with p47, p37 and NU were determined at 400 nM, the concentration that produced the 
maximum changes observed for wild type ND1L. Examples of MM curves for L464P-ND1L are 
shown in Fig. 5A. For WT-ND1L, only NU produced a >2-fold change in ATP turnover, 
reducing apparent kcat values from 3.7 to 1.4 min
-1 (Fig. 5B and Table S3). All three cofactors 
produced >2-fold decreases in apparent Km values, indicating that they enhanced ATP binding 
specifically at the D1 domain (Fig. 5C). It appears that p37 and p47 enhance ATP binding to 
D1, thereby improving the apparent catalytic efficiency of D1 (kcat/Km). Intriguingly, NU 
increased the turnover number in full-length p97 but decreased the turnover number in ND1L, 
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L464E-ND1L and WT-ND1L displayed similar kinetic constants with all three cofactors 
(Figs. 5B-D), indicating that the hydrophobic nature of L464 is not a strict requirement for 
either basal ATPase activity or cofactor regulation at isolated D1 domains. In contrast, the 
L464P-ND1L dramatically reduced the apparent ATP turnover rate (kcat) of D1 by 116-fold, from 
3.7 to 0.032 min-1, with no significant change in the Km value. This observation suggests 
that the position 464 has structural requirements that are vital for D1 ATPase hydrolysis but 
not for ATP binding, consistent with previous comparisons of nucleotide-binding for ND1 
versus ND1L [24]. 
In the presence of p47, L464P-ND1L apparent kcat values (Fig. 5B) increased 14-fold, 
from 0.032 to 0.434 min-1, without significant changes in apparent Km. (Fig. 5C). It appears that 
binding to p47 primarily increases the catalytic ability of the L464P-ND1L protein, possibly 
through stabilization of the linker region that becomes distorted by the proline side chain. With 
p37, L464P-ND1L displayed a 7-fold increase in kcat (Fig. 5B), and the apparent Km value 
decreased 2.7-fold (Fig. 5C). This implies that p37, like p47, may also help stabilize the linker 
region. Cofactor complex NU inhibited L464P-ND1L to undetectable levels of ATPase activity 
across the measured ATP concentrations, similar to NU effects on WT-ND1L. Thus, we cannot 
report kinetic values for NU-regulated L464P-ND1L.  
To summarize our results on full-length p97WT compared to ND1L: (1) p47 does not 
affect activity of ND1L but does regulate p97WT activity in a biphasic manner (Figs. 2B and 4B). 
(2) p47 decreases the apparent Km of both ND1L and p97
WT (Figs. 3C and 5C). (3) NU 
decreases ND1L activity while activating p97WT (Figs. 2D and 4D). (4) p37 caused a 1.5-fold 
increase in activity for ND1L (Fig. 4C) and a 4-fold increase for full-length p97 (Fig. 2C), which 
supports an earlier finding that p37 mainly activates D2 [43]. Overall, these results suggest 
that the mechanisms by which cofactors regulate D1 and full-length p97 (D1 and D2) differ, 
with distinct mechanisms for each cofactor. 
L464P reduced p47 binding to full length p97 but not to the ND1L truncated mutant  
Two evaluate whether changing the conserved L464 to E or P will affect p47 binding, we 
used temperature-related intensity change (TRIC) on a DianthusNT.23 PicoDuo instrument to 
determine the equilibrium binding constant (Kd) for p47 in solution with six p97 proteins (Fig. 
S3). The Kd values are 80, 182, 376 nM for p97
WT, p97L464E, and p97L464P, respectively. These 
results suggested a 4.7-fold reduction of p47 binding affinity caused by proline for full length 
p97. The Kd values are 343, 264, 271 nM for WT-ND1L, L464E-ND1L, and L464P-ND1L, 
respectively. These results suggested a 4.3-fold reduction of p47 binding affinity for ND1L as 
compared to full length p97 and the binding affinity of L464P-ND1L is similar to WT-ND1L. 
Structure of the full-length p97L464P reveals conformational changes caused by changing the 
conserved L464 at the D1-D2 linker 
We showed that L464 is the key residue on the D1-D2 linker for modulating p97 
ATPase function, we want to determine whether the L464 mutation alters the D1-D2 linker 
conformation, thereby affecting the ATPase activity.  We utilized single-particle cryo-EM 
imaging to determine the three-dimensional (3D) structure of the p97L464P (Fig. S4 and S5). 
The cryo-EM reconstruction of the p97L464P showed the same hexameric organization as the 
wild type p97, suggesting that the L464P mutation does not affect the p97 oligomerization (Fig. 
S4A and 6A). The cryo-EM reconstruction showed four clear NTD densities in the down 
conformation, with two NTDs in lower signal levels (Fig. 6A). The density maps allowed us to 
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implying less mobility than the others (Fig. 6A). The unresolved mobile NTD densities may be 
due to their high flexibility, resulting in density flattening. Unlike the homogeneous NTD 
configuration in the wild type [25], the highly flexible NTDs of the p97L464P could be due to the 
linker mutation and the altered communication between domains, resulting in undefined 
positions of the NTDs in cryo-EM density maps. 
 Unlike the NTD densities, the D1 and D2 densities were well resolved in our cryo-EM 
reconstructions. To visualize the details of the structural changes between domains, we then 
attempted to average six D1 and D2 densities symmetrically (Fig. S6).  We further 
superimposed our structure with p97WT (PDB code: 5FTK) (RMSD 1.162 Å) (Fig. 6B). The D1-
D2 linker changes its structure upon L464P mutation, which causes a slight movement of the 
helix-turn-helix (HTH) motif of K543-A569 (Fig. 6C and D). Also, the loop densities (K584-
D598) for the D2 ring in the L464P mutant were missing, suggesting a flexible nature and size 
variation of the D2 ring. These local structural changes could be attributed to the change of the 
loop torsion contributed from the geometric constraints of proline residue (Fig. 6C and D). The 
structural changes of the HTH motif and D2 ring could affect the concerted movement 
between protomers and thereby the ATPase activities.    
L464 mutation decreases the potency of p97 inhibitors 
Because p97 plays a vital role in protein quality control, much has been done in recent 
years to target p97 with potent and specific inhibitors for potential cancer therapy [16, 54-56]. 
These compounds are divided into two major classes: ATP-competitive inhibitors [57, 58] and 
noncompetitive inhibitors [59-61]. We previously evaluated the domain and cofactor-complex 
selectivity of these compounds, finding that communication between the D1 and D2 domains 
changes the ability of each inhibitor to affect ATPase activity [24, 51, 62]. For example, 
mutations within the ND1 domain can significantly increase the IC50 of the D2-specific inhibitor 
ML240 [24]. In addition, the allosteric p97 inhibitor NMS-873 binds in a cavity formed by the 
D1 and D2 regions of the hexamer in close proximity to L464 and p97L464E is 2-fold less 
sensitive to NMS-873 [59]. Furthermore, we established that CB-5083-resistant ovarian cancer 
cells carried E470K and E470D missense mutants that lead to increased p97 ATPase activity 
[63]. Therefore, we want to test if L464 mutants might affect the potency of the ATP-
competitive p97 inhibitors. 
To examine inhibitor potency in relation to L464 mutations, we determined IC50 values 
for four ATP-competitive inhibitors we previously identified -- DBeQ, ML240, ML241, CB-5083) 
[57, 58] and the non-competitive inhibitor (NMS-873) [59] -- against each of the L464 mutants 
and p97WT (Fig. 7). Structures of p97 inhibitors are shown in Figure 7A. The allosteric inhibitor 
NMS-873, which binds close to the D1-D2 linker, had a 2.6-fold increase in the IC50 value for 
the L464E mutant (Fig. 7B). The result corroborates previously published data [59]. The L464A 
and L464P mutants did not significantly affect the IC50 values for NMS-873, which suggested 
that NMS-873 could still bind to these two mutants. 
The ATP-competitive inhibitor DBeQ, which inhibits both D1 and D2 ATPase activities, 
was not affected by L464 mutations, showing similar potencies towards the three linker 
mutants and p97WT (Fig. 7C). On the other hand, the D2-specific inhibitors, ML240, ML241, 
and CB-5083, had 2 to 3-fold increases in IC50 values for the L464 mutants (Figs. 7D and 7E). 
Interestingly, the IC50 increased is more for ML240 than that of CB-5083, which is consistent 
with the finding for E470K and E470D mutants [63]. Because the L464 resides in the D1-D2 
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experiment further supports the conclusion that altering L464 can impair either the D2 




As an AAA+ ATPase protein, p97 acts as the primary molecular machine in several 
cellular processes vital to protein homeostasis and cell survival. Over the past several 
decades, structural analyses and biochemical assays on p97 have identified many essential 
and conserved regions. Mutations in these regions result in cell-based defects and/or ATPase 
activity defects. Several p97 cofactors are thought to direct p97 to various cellular functions via 
discrete and/or overlapping binding sites in the NTD or the C-terminal tails [28, 64, 65]. 
Cofactor binding results in a conformational change of p97, leading to modulation of the 
enzyme kinetics of ATP hydrolysis [66]. Previous studies suggest that p97 disease mutants 
cause imbalanced cofactor binding such as Npl4-Ufd1 but not p47 impairs binding of UBE4B 
to p97 [67] and also impairs UBXD1 binding to p97 [68]. A better understanding of these 
cofactor-regulated changes is imperative for increased knowledge of disease pathogenesis 
and for providing valuable insight into possible therapeutic approaches. 
We explored the role of cofactor-mediated p97 regulation in IBMPFD, a rare disease 
characterized by large cellular inclusion bodies, indicative of possible defects in the p97 
protein degradation pathways [43]. Several disease-causing variants have been biochemically 
characterized and found to raise basal levels of ATPase activity. Therefore, ATPase activity 
alone is not the sole indicator of an efficient, functional p97 protein. We found that three 
disease-causing p97 mutations display altered cofactor regulation. Specifically, the D2 domain 
of IBMPFD mutants could not be activated by either p37 or p47. This suggests that these 
defects may contribute to the pathogenesis of the disease. We also identified amino acids 69 
to 92 of p47 as responsible for the observed difference for p37 and p47 in regulating p97 
ATPase activity [43]. The binding modes of the two cofactors are highly similar and it is 
possible that upon binding to p97 the amino acids 69 to 92 of p47 induce conformational 
changes to case inhibition of both D1 and D2 domain at lower concentration of p47. Without 
this region p37 cannot cause such inhibition. Recently, the role of two related p97 cofactors, 
p47 and p37, in protein phosphatase 1 (PP1) maturation revealed an interesting ubiquitin-
independent unfolding function to regulated PP1 complex disassembly and assembly [69]. 
Here we have demonstrated that the Npl4-Ufd1 heterodimer is an activator of the D2 
domain and an inhibitor of the D1 domain of the p97WT (Fig. 2D and 4D). This supports the 
validity of studying cofactor-regulated p97 activity. The Npl4-Ufd1 heterodimer binds via the 
ubiquitin-like (UBX-L) domain of Npl4, similar to the p47-UBX domain. The binding of the two 
cofactors is mutually exclusive, suggesting that they either bind at the same site or prevent the 
other from binding [70]. The increase in ATPase activity observed for NU may also be involved 
in coordinating and accelerating its function in the ERAD pathway. Tang and Xia showed that 
the N-terminal half of the D1-D2 linker is essential for the activity of the D1 domain. By 
comparing the X-ray crystal structures of the isolated D1 domain with and without the D1-D2 
linker, they showed that the linker region is required to break the symmetric arrangement of 
the D1 ring and enable ATP hydrolysis [23, 42]. Bastola and coauthors reported a potentially 
direct effect of the E470 mutations on the interactions between the ligand and target [63]. 
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p97 by studying the enzymatic activity of point mutants of L464 in both full-length p97 and the 
isolated D1 domain.  
We showed that the L464P mutation reduced by 51% the activity of full-length p97WT 
(in which both the D1 and D2 domains are active ATPases; Figs. 2A and 8A). Consistent with 
the published data on p97L464E [39], both p97L464A (with a smaller side chain) and p97L464E (with 
a negatively charged side chain) retained 100% of p97WT activity. However, the L464P mutation 
disrupted the activity of p97WT, possibly due to the proline side chain caused conformational 
change (Fig. 6). To evaluate the effect of L464P specifically on D1 activity, we made an L464P-
ND1L protein (which has an active D1 domain with the linker) and showed that L464P 
diminished ND1L activity to the levels found for deletion of the entire linker (Figs. 4A and 8B). 
The results suggest that the structural flexibility of L464 in the D1-D2 linker is important for the 
basal activity of p97WT. The severe effect of the proline mutation on the isolated D1 domain 
(L464P-ND1L) indicates that the proper structure of the D1-D2 linker is vital to D1 function. 
Due to the proximity of L464 to the nucleotide-binding pocket of the D1 domain (Fig.1B), it is 
possible that its flexibility is required for the overall movement that occurs during ATP 
hydrolysis, but not ATP binding. This interpretation is supported by the fact that the apparent Km 
value of L464P-ND1L does not differ from the apparent Km value of WT-ND1L (Fig. 5C), but the 
apparent kcat value of L464P-ND1L is 115-fold lower than the WT-ND1L value (Table S2). 
Although the basal ATPase activities of p97L464A and p97L464E are similar to that of the 
p97WT, the mutations caused severe defects in the clearance of the ERAD substrate TCR-α-GFP 
[39] and the UFD pathway reporter (UbG76V-GFP) (Fig. S1). Here we showed that the cellular 
defects observed with the L464 mutants may be due to abnormal cofactor-regulated p97 
enzyme function. The L464 mutants and the full-length p97WT displayed similar basal steady-
state kinetics, but the mutants had a complete loss of p47-regulated inhibition (Figs. 2-3). 
Instead, p47 had only single-phase activation with the mutants, which appeared to enhance the 
phase 2 rebound normally observed with the p97WT. L464P-p97 had much greater activation, 
compared to the more flexible alanine and glutamate mutants, for the three cofactors tested 
(Figs. 2B-D). Furthermore, p97L464A and p97L464E actually reduced activation by p37 (Fig. 2C) 
and NU (Fig. 2D), whereas L464P enhanced activation of full-length p97 by both p37 and NU. 
These three-point mutations in the D1-D2 linker region clearly altered cofactor-regulated p97 
ATPase activities. 
Previous structural studies on p97 and yeast homolog Cdc48 have provided valuable 
insight on this versatile ATPase [52, 71-73]. p97WT is highly dynamic upon cofactor binding, 
and some mutation sites were found to stabilize the complex; for example, p97A232E,E578Q 
double mutations were introduced in Pan et. al [37]. NMR study suggested that an intrinsically 
disordered region regulates the interaction between p47 and the truncated p97-ND1L [52]. 
Shp1, a yeast p47 homolog, was used to pull down Cdc48 in the presence of nonhydrolyzable 
ATP analog with an endogenous polypeptide. The cryo-EM analysis of this complex implied a 
hand-over-hand mechanism of substrate translocation of the AAA+ ATPase [74]. Using 
Cdc48E588Q, a D2 ATPase-dead mutant complex with Npl4-Ufd1 can pull a ubiquitinylated 
substrate through the central pore [75]. 
Blythe et. al showed that in the presence of ATP, p97WT has 50% up and down NTD 
and the NTDs of the p97A232E are all in up position [36]. In the presence of ADP, all resolved 
p97WT NTD showed down positions and p97A232E show more than 50% mobile NTD and 20% 
visible down position and less than 10% up position [26]. In our p97L464P structure, we did not 
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and two NTDs in lower signal levels (Fig. 6A). Our results indicate that the resolved NTDs in 
the p97L464P resemble the NTDs in the ADP-bound p97WT. 
Recently, Pan and coauthors solved several cryo-EM structures of p97A232E, E578Q 
with Npl4-Ufd1; they used the mutant A232E to lock N-domain in a more up-conformation and 
E578Q to block D2 ATP hydrolysis to enable a stable complex with Npl4/Ufd1 and 
polyubiquitinated substrate, and they observed conformational change at L464 amino acid by 
comparing the ATPγS-bound non-translocating structure with the ATPγS-bound plus substrate 
(PDB ID: 7JY5) [37, 76]. By comparing two ATPγS-bound p97 structures, with and without 
substrate, they demonstrated L464A has reduced unfoldase activity using the polyubiquitinated 
substrate [76]. In vitro study using artificial mutant such as E578Q to abolish ATP hydrolysis is 
one of the methods to enable visualization of the dynamic p97 protein. Similarly, even though 
ATPase activity alone is not the sole indicator of p97 function, it does provide direct evidence of 
how a single amino acid change can change it basal and cofactor-regulated ATPase activities. 
We think the difference in cofactor-regulated ATPase activity can potentially indicate difference 
in regulating p97’s endogenous substrates associated with a specific cofactor, but this remains 
to be determined. 
In recent years, an upsurge in p97 inhibitor development has yielded promising 
starting points for future therapies. A number of structure-activity relationship studies have 
been aimed towards tailoring inhibitors to specific p97 functions [49, 51, 60-62, 77]. We found 
that L464 is critical for determining the functionality of p97 inhibitors. Specifically, mutating 
L464 diminished by 3-fold the inhibitory effects of D2 ATP-competitive inhibitors, ML240 and 
ML241 (Fig. 7D and E). We reconfirmed findings that an L464 mutant reduced the potency of 
NMS-873 (Fig. 7B), an inhibitor that binds in the linker region [59]. From these results, we 
conclude that L464 is critical for maintaining the correct conformation of the linker region, and 
that disturbing the conformation of the linker can impact how D2-selective ATP competitive 
inhibitors bind to the D2 ATPase domain. 
Our model suggests that the conserved L464 in the D1-D2 linker (22 amino acids, Fig. 
8) is necessary to maintain communication among the domains of p97, including NTD, D1, and 
D2, regardless of their distances from one another in space. The L464P mutation changes the 
conformation of the linker region, lowering the efficiency of ATP hydrolysis by reducing 
ATPase activities (Fig. 8A). For the isolated D1 domain with the linker (ND1L), the L464P 
mutation induces a conformational change that nearly abolishes its ability to hydrolyze ATP 
(Fig. 8B). The L464P-ND1L is enzymatically comparable to the ND1 protein, which lacks the 
linker region entirely [24]. This substantial loss of activity compared to WT-ND1L demonstrates 
the importance of the linker region for D1 ATPase function, a finding consistent with our 
previous results [24]. In addition, we propose that although the L464P mutation alters the 
conformation of the p97 D1-D2 linker, the presence of p47 restores the conformation to some 
degree, through stabilization of the linker region of L464P (Fig. 8B). This interpretation would 
explain why p47 has no appreciable effect on WT-ND1L ATPase activity, but activates the 
L464P-ND1L mutant by 12-fold (Fig. 5B and 8B). 
This study adds to our growing understanding of p97 and its function. We have 
determined that the conformation of the linker region is crucial to ATP hydrolysis at the D1 and 
D2 domains. We identified the importance of these regions in communication within the 
enzyme during cofactor-regulated ATPase activity and demonstrated that three p97 cofactors 
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p97 cofactors but published result suggests that in normal condition, most p97 cofactors are 
not associated with p97 and the association can be enhanced under some conditions. For 
example, Xue and coauthors used size exclusion chromatography to separate cellular p97 and 
p97 cofactor complexes in HEK293 coupled with mass spectrometry to infer that the cofactors 
interaction with p97 are very dynamic; they also found p47 and Npl4-Ufd1 do not cofractionate 
with p97 in unperturbed cell lysate and upon p97 inhibition by an allosteric inhibitor NMS-873 
enhanced formation of the complexes, but most of cofactors are still not associated with p97 
[78]. Therefore, future studies of the remaining known UBX cofactors are warranted. 
Additionally, comprehensive structural data of p97 cofactors are not available. For example, 
even though p47 has been studied with great interest since its discovery in 1997 [29] and the 
structures of p47 revealed that conformational changes in p97 are induced [29, 79, 80]. 
Structural data for p97 bound with the full-length p47 and other p97 cofactors would provide 
evidence for the conformational changes resulting from cofactor interaction. In addition, it is 
likely that the p97 function is modulated by its substrates, as well as its cofactors. Future work 
should examine the role that endogenous substrates play in cofactor-regulated p97 activity. 
Given our knowledge gained from more thoroughly studying the enzyme-cofactor relationship, 
it is reasonable to infer that each p97 enzyme-cofactor complex is fine-tuned for the 
microenvironment where it performs its role. Therefore, a better understanding of these 
complexes will yield valuable insights into the biochemical intricacies of their functions. We 
believe that our research provides new information useful for understanding how p97 cofactors 
regulate p97 function and for developing p97-specific therapeutic agents. 
 
Materials and Methods  
Ubiquitin fusion degradation pathway reporter assay. The HeLa cells that stably expressed 
UbG76V-GFP are described previously [46,48]. Cells were treated with TrypLE Select (Thermo 
Fisher) and counted the day before transfection. Cells were then plated, 3000 cells per well, in 
30uL of 10% FBS clear growth medium. Cells were observed to be 80-90% confluent the day of 
transfection. Transfection complexes for each sample were prepared by mixing 2 μg of DNA, 
3uL of BioT reagent (Bioland Sci), and 100 μL of Serum-free DMEM, and incubating for 25 
minutes at 25°C. 10 μL of the DNA-BioT complexes were then added directly to each well 
containing cells and mixed on a rocker. Plates were incubated at 37°C in a CO2 incubator for 24 
hours, then read using ImageXpress (Molecular Device). 
Preparation of p97 ATPase proteins. Plasmids used for generating p97 and ND1L proteins can 
be found in supplemental Table S6. Proteins were purified as previously described [24, 57]. 
Determining IC50 values of p97 inhibitors in ATPase assays. The detailed method was described 
previously [24]. Inhibition of human p97 (25 nM monomer) was carried out in assay buffer (50 mM Tris 
(pH 7.4), 20 mM MgCl2, 1 mM EDTA and 0.5 mM TCEP) containing 0.01% Triton X-100 and 200 μM 
ATP. The 8-dose titration was performed at 40, 13.3, 4.4, 1.48, 0.49, 0.16, 0.05, and 0 μM. ATPase 
activity was determined through the addition of Biomol Green Reagent (Enzo Life Sciences). NMS-873 
was purchased from Xcess Biosciences Inc. 
Gel filtration to confirm the stability of the mutant p97 and p47 complex. Gel filtration was 
carried out with a Superdex 200 10/300 GL (GE Healthcare). The column was calibrated with 
molecular weight (MW) standards kit (Sigma). The standards are Blue Dextran [MW is 2000 
kDa; used to determine the void volume (Vo) of the column], β-amylase (200 kDa), alcohol 
dehydrogenase (150 kDa), bovine serum albumin (66 kDa), and carbonic anhydrase (29 kDa). 
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where Ve is the elution volume of the MW standard and Vo is the void volume. To determine 
the apparent molecular weight of WT-ND1L, L464E-ND1L, and L464P-ND1L, we injected 100 
L of 20 M proteins, determined their elution volumes (Ve), and then calculated apparent 
molecular weights using the equation obtained from the standard curve. The calculated MW 
was divided by the monomer MW to calculate the oligomeric state. 
Cryo-EM data collection and image analysis. For p97L464P mutant, a holey-carbon C-flat grid 
(2/1 4C; Protochips, Morrisville, NC) was glow-discharged for 15 seconds using a Pelco 
easiGlow glow-discharge system (Ted Pella, Redding, CA). 6 µL protein sample at a 
concentration of 0.2 mg/mL was applied onto the pretreated grid, and the excess solution was 
blotted away by a filter paper (Whatmann 55/20 nm) using a Thermo Fisher/FEI Vitrobot Mark 
IV automated freeze plunger (Thermo Fisher/FEI, Hillsborough, OR) for 6 seconds in a 
chamber with a humidity of 100%. The grid was then quickly plunged frozen into liquid ethane 
and transferred to a grid storage. Particle homogeneity and ice thickness of the grid specimen 
were screened using a FEI Tecnai TF20 TEM.  Grids with a thin ice and a homogeneous 
protein dispersion were used for the subsequent cryo-EM data collection.  
 The grid specimen was imaged using a Thermo Fisher/FEI Titan Krios TEM at an 
accelerating voltage of 300 keV at the Eyring Materials Center (EMC) at Arizona State 
University (ASU), Tempe, AZ. Cryo-EM movies were recorded using a Gatan K2 Summit direct 
electron detector (DED) camera (Gatan, Pleasanton, CA). Defocus range was set to -0.8 to -
2.5 µm. Nominal magnification was 48,077✕, resulting in a physical pixel size of 1.04 Å/pixel 
at the specimen level. The movie data was recorded at a counted rate of 8.096 e-/pixel/sec 
and a sub-frame rate of 200 msec in counting mode. Total exposure was 8 seconds, 
accumulating to a dosage of 64.8 e-/Å2. Beam-image shift was applied to accelerate the data 
acquisition [81].  The data collection was automated using the customized SerialEM macros 
(version 3.9) [82]. 
 The image processing for the p97L464P dataset was generally conducted using 
cryoSPARC software (version 3.1) [83]. 4,490 movies were unpacked and imported into 
cryoSPARC program. The frame registration and averaging were performed using patch 
motion correction. The defocus parameters were estimated using patch CTF estimation. The 
particle selection was performed using Topaz program (version 0.2.3) [84]. The two-
dimensional (2D) unsupervised classification was performed to generate the averages from 
the selected particle pool. The classes with discernible features were selected for ab initio 
volume generation using stochastic gradient descent (SGD) method [83]. Further particle 
image curation was performed using 2D image classification, ab initio 3D generation supplied 
with a higher k value and heterogeneous refinement. The final 3D density was then refined 
against the experimental images using homogeneous refinement and non-uniform refinement 
[85]. The generated maps reached final resolutions of 5.16 Å. The final resolution of the 
density map was determined using the golden FSC criteria at 0.143 cutoff [86]. To visualize 
the details of the D1 and D2 domains, the densities of the D1 and D2 domains were 
symmetrically averaged supplied with a local mask only containing D1 and D2 domains. The 
resolution of the symmetrically averaged density reaches 4.12 Å. The processing schematics 
and data statistics are shown in Fig. S4 and Table S6.  
Modeling. The templates used for atomic modeling were the previous coordinates of p97 (PDB 
code: 5FTK) [25]. The templates were first docked into individual cryo-EM densities using ‘Fit 
in the Map’ function in UCSF Chimera (version 1.14) [87]. The fitted model was manually 
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‘phenix.real_space_refine’ program in Phenix software package (version 1.18.2-3874) [89]. 
Hydrogen atoms were added using ‘phenix.reduce’ for the model refinement and removed 
after the refinement. Secondary structure restraints were applied during the model refinement. 
The refinement and validation statistics was listed in Table S6. The figures for the cryo-EM 
density maps and atomic models were prepared using UCSF Chimera or ChimeraX (version 
1.0) [90]. 
BIOMOL Green ATPase assay. Detection of ATPase activity using BIOMOL Green reagent 
(Enzo Life Sciences) was performed as previously described [43]. Purified p97 or ND1L 
proteins (25 µL of 50 µM; final concentration = 25 nM monomer concentration) were used with 
400 nM cofactor proteins. For generating Michaelis-Menten (MM) curves, at least 8 
concentrations of ATP were utilized in at least 6 replicate reactions, and all calculations were 
made using GraphPad Prism 7.0 by fitting data to Equation 1. 
ν = Vmax·[ATP]/(Km + [ATP]) (1). 
Molecular graphics. The figure of the p97 structures was prepared using UCSF ChimeraX [90] 
with the atomic coordinates from the PDB codes of 5TFN (down) [77], 5TFM (up) [77], and 
1S3S (p97N-D1-p47UBX) [71].    
 
p47 binding affinity measurements. The binding affinity (Kd values) between p47 and p97
WT or 
p97 mutants was determined by measuring the temperature-related intensity change (TRIC) 
signals using a Dianthus NT.23 instrument (Nano-Temper Technologies, München, Germany).  
p47 was labeled with a RED-NHS dye using the Monolith Protein Labeling Kit RED-NHS 
second-generation (Nano-Temper Technologies, CAT# LO-L011).  Full-length wild type or 
mutant p97 was titrated against 10 nM of p47-NHS in two-fold steps from 2.8 µM to 1.37 nM in 
20 µL working buffer (20 mM HEPES (pH 7.4), 150 mM KCl, 1 mM MgCl2, 5% (w/v) glycerol, 
and 0.0025% (v/v) Tween 20). Assays were performed in a Dianthus 384-well plate in three 
independent experiments. Data from three independent measurements were fitted using non-
linear regression analysis in Prism 7.0.   
Data availability. Cryo-EM density maps were deposited in the Electron Microscopy Data Bank 
(EMDB) under accession numbers of EMD-23775 and EMD-23776 (symmetrized) and the 
Protein Data Bank (PDB) under accession numbers of 7MDM and 7MDO (symmetrized). All 
data are available from the corresponding author upon request.  
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Figure 1. p97 domain organization. (A) p97 AAA+ ATPase domains. p97 consists of an N 
terminal region (green; residues 1-184) containing cofactor binding sites and the disease-
related, conserved arginine residue (R155), followed by the D1 (orange; residues 211-459) and 
D2 (orange red; residues 482-762) ATPase domains.  These two domains are joined by a linker 
(blue; residues 460-481), containing a highly conserved leucine residue (L464). (B) Structures 
of the p97 monomer with the N-domain in conformations. At the left is the up-conformation 
(PDB code: 5FTN), and at the right is the down-conformation (PDB code: 5FTM) [77]. (C) 
Superposition of the crystal structure of the p97ND1-p47UBX (PDB code: 1S3S) [71] with the 
structure of the full-length p97 in the down conformation (grey; PDB code: 5FTM). The structure 
of the p47-UBX is shown in pink. The distances of p47-UBX from the D1 domain, the D1-D2 
linker, and the D2 domain are 34.7 Å, 47.8 Å, and 52.2 Å, respectively. 
Figure 2. ATPase activity of full-length (FL) D1-D2 linker mutants and concentration-
dependent effects of cofactors. (A) ATPase activity of FL p97 proteins normalized to WT 
activity and measured with 200 μM ATP (n=8). (B-D) ATPase activity of WT-p97 (blue) and D1-
linker mutants L464E (red), L464A (green), and L464P (purple) at increasing concentrations (0-
800 nM) of cofactors (B) p47 (C), p37, and (D) Npl4-Ufd1 (NU). Experiments were performed 
using p97 proteins at 4.17 nM hexamer and 200 µM ATP, and the activity of each p97 protein 
was normalized to its basal activity in the absence of cofactors (n=6). All error bars indicate ± 
SD. 
Figure 3. Steady-state kinetic analysis of full-length D1-D2 linker mutants and cofactor-
enzyme complexes. (A) Michaelis-Menten curves of ATP hydrolysis by L464P-p97 with and 
without cofactors (n=10). (B-D) Steady-state kinetic analyses of WT, L464A, L464E, and 
L464P-p97 catalyzed ATP hydrolysis performed alone (solid bar) and in the presence of 400 
nM p47, p37, or Npl4-Ufd1 (NU) (n=8). Dependence of apparent kcat (B), apparent Km (C), and 
apparent kcat/Km (D) values on cofactors p47 (horizontal stripes), p37 (vertical stripes), and NU 
(checkered) are shown for WT-p97 (blue), L464A (green), L464E (red), and L464P (purple). 
Experiments were performed using p97 proteins at 4.17 nM hexamer and 30-750 µM ATP. All 
error bars indicate ± SD. 
Figure 4. ATPase activity of WT-ND1L and ND1L-linker mutants and concentration-
dependent effects of cofactors. (A) ATPase activity of ND1L proteins normalized to WT-
ND1L (n=8). (B-D) ATPase activity of WT-ND1L (blue open triangles) and ND1L-linker mutants 
L464E-ND1L (red open squares) and L464P-ND1L (purple open circles) at increasing 
concentrations (0-800 nM) of cofactors p47 (B) (n=6), p37 (C) (n=12), and Npl4-Ufd1 (NU; D) 
(WT and L464E n=9; L464P n=4). Experiments were performed using ND1L proteins at 4.17 
nM hexamer for WT and L464E, 20.85 nM hexamer for L464P-ND1L, and 200 µM ATP. All 
error bars indicate ± SD. 
Figure 5. Steady-state kinetic analysis of WT-ND1L, ND1L-linker mutants, and cofactor-
enzyme complexes. (A) Michaelis-Menten curves of ATP hydrolysis by L464P-ND1L in buffer 
(circles), p47 (diamonds), and p37 (triangles). (B-D) Steady-state kinetic analyses of WT, 
L464E, and L464P-ND1L ATP hydrolysis performed alone (solid bar) and in the presence of 
400 nM p47, p37, or NU. Dependence of apparent kcat (B), apparent Km (C), and apparent 
kcat/Km (D) values on cofactors p47 (horizontal stripes), p37 (vertical stripes), and NU 
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Experiments were performed using ND1L proteins at 4.17 nM hexamer and 10-121 µM ATP. All 
error bars indicate ± SD and n=9.  
Figure 6. Cryo-EM structural analysis of the p97L464P mutant. (A) Cryo-EM density map and 
model of human p97L464P.  NTD, D1 and D2 domains are dark green, orange and orange red, 
respectively. Linkers and C-terminal tail are colored in grey. Outer white surface and colored 
surface densities are present in signal levels of 2.7𝝈 and 7.6𝝈, respectively. Scale bar indicates 
25 Å. (B) Superposition of structures of the p97L464P mutant and ADP-bound p97WT (PDB code: 
5FTK). The RMSD of the superimposed structures is 1.162 Å. p97L464P and p97WT are in blue 
and golden yellow, respectively. (C) Enlarged view of the mutated residues from leucine 464 
(golden yellow) to proline (blue). (D) Enlarged view of the superimposed D1-D2 linkers and 
surrounding areas. D1-D2 linker, helix-turn-helix (HTH) motif (K543-A569) and flexible central 
D2 loop (586-598) are colored.  Bound nucleotides are shown in sticks.  
Figure 7. Effect of D1-D2 linker mutations on potency of p97 inhibitors. (A) Structures of 
p97 inhibitors. IC50 values for p97 inhibitors (B) NMS-873, (C) DBeQ, (D) ML240, (E) ML241, 
and (F) CB-5083 for full-length WT-p97 and L464 mutants at 200 µM ATP. All error bars 
indicate ± SD, and n=3. 
Figure 8. Model for the role of the D1-D2 linker region in regulating p97 ATPase activity. 
(A) Mutation of L464 to Pro reduces basal ATPase activity of full-length p97 by 50% and 
binding with excess p47 cofactor inhibits p97WT activity to be 80% of WT but active p97L464P to 
be 200% of WT. (B) L464P mutation in the ND1L protein produces a severe defect, equal to 
that of complete truncation of the D1-D2 linker region (1.6% of p97WT) and binding to excess 
p47 cofactor does not affect ND1L activity but enhances binding to ATP, whereas binding to  
L464P-ND1L affects the conformation of the D1-D2 linker of L464P and enhance activity to 
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